BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, April 7, 2026
Home » Topics » Financings, BioWorld

Financings, BioWorld
Financings, BioWorld RSS Feed RSS

Financings for Feb. 6, 2026

Feb. 6, 2026
Biopharma and med-tech companies raising money in public or private financings, including: Angitia, Collplant, GE Medical Holding, Generate, Exact, Inspira, LB, Myndtec.
Read More
Hand holding dollar sign
Biopharma financings January 2026

2026 kicks off with $10.8B January financing haul

Feb. 6, 2026
By Amanda Lanier
No Comments
Total biopharma financings rose to $10.79 billion in January 2026, up from $9.08 billion in December. The monthly total nearly matched the January 2024 record of $10.9 billion, far exceeding the $6.82 billion average monthly haul in 2025.
Read More

Financings for Feb. 5, 2026

Feb. 5, 2026
Biopharma and med-tech companies raising money in public or private financings, including: Biolab, Exxel, Imbed, Izotropic, Pavmed, Stratus, Third Arc.
Read More
IPO money

Eikon’s $381M raise represents largest biopharma IPO in two years

Feb. 5, 2026
By Karen Carey
No Comments
Pricing the third and largest biopharma IPO of 2026, Eikon Therapeutics Inc. raised $381 million in an upsized offering of 21.18 million shares of common stock at $18 each, the high point of its price range.
Read More
Chromosome with shortened telomeres
Newco news

ALTx formed to drug pathway by which cancer cells become immortal

Feb. 5, 2026
By Nuala Moran
No Comments
Newco ALTx Therapeutics Ltd. has launched with a £12.55 million (US$17.1 million) seed round to develop inhibitors of the alternative lengthening of telomeres (ALT) pathway, by which 10% to 15% of cancers become immortal.
Read More

Financings for Feb. 4, 2026

Feb. 4, 2026
Biopharma and med-tech companies raising money in public or private financings, including: Adlai Nortye, Medx, Polaryx, Salspera, Sangamo, Sonovascular, Vaxcyte.
Read More

Hair loss drugmaker Veradermics floats upsized $256M US IPO

Feb. 4, 2026
By Marian (YoonJee) Chu
No Comments
Veradermics Inc. raised $256.3 million from an IPO on the New York Stock Exchange Feb. 4. The proceeds will fund three ongoing phase II/III clinical trials of VDPHL-01, its novel oral formulation of Rogaine (minoxidil) to treat pattern hair loss in men and women.
Read More

Financings for Feb. 3, 2026

Feb. 3, 2026
Biopharma and med-tech companies raising money in public or private financings, including: Affluent, Santé Ventures.
Read More
Maud Eijkenboom, CEO, Lixa Pty Ltd.

Switching off resistance: Lixa’s bold AMR bet

Feb. 3, 2026
By Tamra Sami
No Comments
Lixa Pty Ltd. has formed a partnership with the Global Antibiotic Research & Development Partnership and announced a AU$28 million (US$20 million) series B round to take Neox-121 to the clinic to fight antimicrobial resistance.
Read More
Interfering RNA (RNAi)
Drug design, drug delivery & technologies

Genentech licenses Sanegene’s RNAi asset in $1.7B deal

Feb. 3, 2026
By Marian (YoonJee) Chu
No Comments
Genentech Inc. is paying $200 million up front and up to $1.5 billion in milestone payments to license one of Suzhou Sanegene Bio Inc.’s RNAi programs. Metabolic and autoimmune-focused Sanegene did not disclose specifics around the licensed candidate, except that it was derived from its LEAD (Ligand and Enhancer Assisted Delivery) platform.
Read More
Previous 1 2 … 5 6 7 8 9 10 11 12 13 … 321 322 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 7, 2026.
  • Hengrui discovers new Nav1.8 blockers

    BioWorld Science
    Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
  • Cancer and blood cells

    Hematopoietic stem cell research points to leukemia’s early roots

    BioWorld Science
    Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
  • 3D illustration of antibodies

    Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis

    BioWorld Science
    Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for April 7, 2026
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing